title: Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema.
abstract: OBJECTIVE
  To describe the bioactivity of an intercellular adhesion molecule inhibitor (efalizumab) in a patient with refractory uveitic macular edema.
  
  
  METHODS
  A 55-year-old man presented with idiopathic autoimmune uveitis and associated macular edema, which could not be controlled by regional and systemic corticosteroid and selected immunomodulatory therapy. Efalizumab was administered as subcutaneous injections.
  
  
  RESULTS
  After 37 weekly injections of efalizumab, the uveitic macular edema was successfully eliminated. Six months following discontinuation of efalizumab, there were no signs of recurrent inflammation.
  
  
  CONCLUSIONS
  Further investigation of the role of intercellular adhesion molecule inhibitors in the management of uveitic macular edema is indicated.
authors.affiliation: Wilmer Eye Institute, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA.
authors.forename: Jianmin
authors.initials: J
authors.lastname: Wang
authors.forename: Mohamed
authors.initials: M
authors.lastname: Ibrahim
authors.forename: Peykan
authors.initials: P
authors.lastname: Turkcuoglu
authors.forename: Elham
authors.initials: E
authors.lastname: Hatef
authors.forename: Afsheen
authors.initials: A
authors.lastname: Khwaja
authors.forename: Roomasa
authors.initials: R
authors.lastname: Channa
authors.forename: Diana V
authors.initials: DV
authors.lastname: Do
authors.forename: Quan Dong
authors.initials: QD
authors.lastname: Nguyen
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D001327:Autoimmune Diseases / Q000150:complications*; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors*; D006801:Humans; D007279:Injections, Subcutaneous; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D015866:Uveitis, Posterior / Q000150:complications*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015815:Cell Adhesion Molecules; C472181:efalizumab